

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-357**

**21-358**

**MICROBIOLOGY REVIEW**

# Product Quality Microbiology Review

27 Dec. 2001

NDA: 21-357 and 21-358

Name of Drug: MultiHance

Review Number: 2

Submission Date: Fax Date - 12/15/01

Applicant: Bracco Diagnostics Inc.

Name of Reviewer: Stephen E. Langille Ph.D.

## Product Quality Microbiology Data Sheet

- A.
1. **NDA/:** 21-357-BI & 21-358-BI
  2. **REVIEW NUMBER:** 1
  3. **REVIEW DATE:** 12/7/01
  4. **TYPE OF SUPPLEMENT:** N/A
  5. **SUPPLEMENT PROVIDES FOR:** N/A
  6. **APPLICANT/SPONSOR**

**Name:** Bracco Diagnostics Inc.  
P.O. Box 5225  
Princeton, NJ 08543

**Representative:** Melanie Benson  
**Telephone:** (609) 514-2254
  7. **MANUFACTURING SITE:** Bracco Imaging S.p.A.  
via E. Folli, 50  
20134 Milan Italy
  8. **DRUG PRODUCT NAME:**

Proprietary: MultiHance  
Non-proprietary: Gedobenate Dimeglumine  
Drug Priority Classification: Standard
  9. **DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY:**
    - Injectable solution
    - Intravenous
    - 529 mg/mL
  10. **METHOD(S) OF STERILIZATION:**  $\zeta$  \_\_\_\_\_  $\jmath$
  11. **PHARMACOLOGICAL CATEGORY:** Imaging agent for MRI of the \_\_\_\_\_ CNS

- 
- B.
1. **DOCUMENT/LETTER DATE:** April 27, 2001
  2. **RECEIPT DATE:** April 30, 2001
  3. **CONSULT DATE:** May 2, 2001
  4. **DATE OF AMENDMENTS:** December 5, 2001 (Subject of this review)
  5. **ASSIGNED FOR REVIEW:** December 20, 2001
  6. **SUPPORTING/RELATED DOCUMENTS:**
- C. **REMARKS:** Melanie Benson was notified on October 28, 2001 of some minor microbiology deficiencies in NDAs 21-357 and 21-358. On December 5, 2001, Ms. Benson sent a fax response to the microbiology deficiencies. The information provided was found to be satisfactory in support of the original applications and NDAs 21-357 and 21-358 were recommended for approval. Formal copies of Bracco's responses to the microbiology deficiencies have been submitted NDAs 21-357-BI and 21-358-BI and have been similarly recommended for approval.

Appears This Way  
On Original

**Executive Summary**

**I. Recommendations**

**A. Recommendation on Approvability -**  
NDA 21-357-BI and 21-358-BI are recommended for approval from the standpoint of microbial product quality.

**B. Recommendation on Phase 4 Commitments and/or Agreements, if Approvable**

N/A

**II. Summary of Microbiology Assessments**

**A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology**  
MultiHance is compounded in a class \_\_\_\_\_

**B. Brief Description of Microbiology Deficiencies**  
There were no microbiology deficiencies

**C. Assessment of Risk Due to Microbiology Deficiencies**  
N/A

**III. Administrative**

**A. Reviewer's Signature** \_\_\_\_\_

**B. Endorsement Block**  
In DFS

**C. CC Block**  
In DFS

5 Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential

§ 552(b)(5) Deliberative Process

§ 552(b)(5) Draft Labeling

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Stephen Langille  
1/4/02 11:04:12 AM  
MICROBIOLOGIST

Peter Cooney  
1/4/02 11:58:34 AM  
MICROBIOLOGIST

# Product Quality Microbiology Review

07 Dec. 2001

NDA: 21-357 and 21-358

Name of Drug: MultiHance

Review Number: 1

Submission Date: April 27, 2001

Applicant: Bracco Diagnostics Inc.

Name of Reviewer: Stephen E. Langille Ph.D.



- 
- B.
1. **DOCUMENT/LETTER DATE:** April 27, 2001
  2. **RECEIPT DATE:** April 30, 2001
  3. **CONSULT DATE:** May 2, 2001
  4. **DATE OF AMENDMENTS:**
  5. **ASSIGNED FOR REVIEW:** May 7, 2001
  6. **SUPPORTING/RELATED DOCUMENTS:**
- C. **REMARKS:** A separate application, NDA 21-358, was submitted for the MultiHance pharmacy bulk pack. NDAs 21-257 and 21-358 will be reviewed together. The [redacted] package was provided in volume 4.7 of NDA 21-357. Melanie Benson, from Bracco Regulatory Affairs, was contacted on 10-28-01 regarding container/closure integrity testing and holding time issues relating to these applications. A faxed response was sent on 12-5-01.

Appears This Way  
On Original

**Executive Summary**

**I. Recommendations**

**A. Recommendation on Approvability -**  
NDA 21-357 and 21-358 are recommended for approval from the standpoint of microbial product quality.

**B. Recommendation on Phase 4 Commitments and/or Agreements, if Approvable**

N/A

**II. Summary of Microbiology Assessments**

**A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology**  
MultiHance is compounded in a \_\_\_\_\_

**B. Brief Description of Microbiology Deficiencies**  
There were no microbiology deficiencies

**C. Assessment of Risk Due to Microbiology Deficiencies**  
N/A

**III. Administrative**

**A. Reviewer's Signature** \_\_\_\_\_

**B. Endorsement Block**  
In DFS

**C. CC Block**  
In DFS

11 Page(s) Withheld

§ 552(b)(4) Trade Secret / Confidential

§ 552(b)(5) Deliberative Process

§ 552(b)(5) Draft Labeling

11